microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

PubWeight™: 2.10‹?› | Rank: Top 2%

🔗 View Article (PMC 2943754)

Published in Blood on December 12, 2008

Authors

Aldo M Roccaro1, Antonio Sacco, Changzhong Chen, Judith Runnels, Xavier Leleu, Feda Azab, Abdel Kareem Azab, Xiaoying Jia, Hai T Ngo, Molly R Melhem, Nicholas Burwick, Lyuba Varticovski, Carl D Novina, Barrett J Rollins, Kenneth C Anderson, Irene M Ghobrial

Author Affiliations

1: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

Articles citing this

Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28

MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation (2010) 2.03

MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem (2009) 1.73

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood (2009) 1.40

Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism. PLoS One (2009) 1.17

Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget (2014) 1.13

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood (2010) 1.11

MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. Autophagy (2012) 1.10

Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease. Mol Neurodegener (2009) 1.07

The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics (2012) 0.98

Microarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor. BMC Genomics (2013) 0.97

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget (2010) 0.93

Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol (2014) 0.92

Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther (2015) 0.92

Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J (2013) 0.88

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia (2014) 0.87

Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol (2010) 0.84

Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci (2013) 0.84

Over-expression of microRNA-494 up-regulates hypoxia-inducible factor-1 alpha expression via PI3K/Akt pathway and protects against hypoxia-induced apoptosis. J Biomed Sci (2013) 0.82

MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer J (2011) 0.81

Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol (2011) 0.80

Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol (2013) 0.79

Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica (2012) 0.78

The bone marrow microenvironment in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk (2013) 0.77

Novel treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk (2013) 0.77

Novel agents in Waldenström macroglobulinemia. Clin Investig (Lond) (2011) 0.77

How to manage Waldenstrom's macroglobulinemia. Leukemia (2013) 0.77

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia (2015) 0.76

Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk (2011) 0.76

The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol (2011) 0.75

Novel agents in Waldenstrom Macroglobulinemia. Open J Hematol (2010) 0.75

Genetic factors and pathogenesis of Waldenström's macroglobulinemia. Curr Oncol Rep (2013) 0.75

MicroRNAs to know in Waldenstrom macroglobulinemia. Blood (2009) 0.75

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. Oncogene (2015) 0.75

Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet (2013) 0.75

Articles cited by this

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62

Prediction of mammalian microRNA targets. Cell (2003) 53.70

Combinatorial microRNA target predictions. Nat Genet (2005) 50.48

MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83

Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60

Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17

MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56

Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet (2005) 15.96

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59

Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96

Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature (1999) 10.48

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature (1999) 8.42

In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60

BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol (2005) 6.57

Reciprocal actions of REST and a microRNA promote neuronal identity. Proc Natl Acad Sci U S A (2006) 5.78

MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54

MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40

NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94

Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol (2006) 4.67

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76

Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet (2008) 2.01

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer (2006) 1.98

miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer (2006) 1.77

Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood (2002) 1.67

Waldenström macroglobulinaemia. Lancet Oncol (2003) 1.55

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50

Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle (2006) 1.42

Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol (2006) 1.41

Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood (2008) 1.36

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood (2002) 1.35

Incidence of Waldenström's macroglobulinemia. Blood (1993) 1.27

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol (2007) 1.26

PAK is regulated by PI3K, PIX, CDC42, and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced p38 pathway. J Biol Chem (2008) 1.24

3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J Biol Chem (2005) 1.07

Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res (2007) 1.07

A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20. Oncogene (2007) 0.98

Articles by these authors

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21

Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07

The knockout mouse project. Nat Genet (2004) 7.80

Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol (2003) 7.38

An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med (2003) 6.61

Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01

Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96

NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94

Multiple myeloma. Lancet (2009) 4.60

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46

Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33

CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res (2005) 4.14

Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98

The RNAi revolution. Nature (2004) 3.96

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66

Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA (2002) 3.63

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60

Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25

Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75

Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65

Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58

Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes (2007) 2.54

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54

Genetic analysis of the subunit organization and function of the conserved oligomeric golgi (COG) complex: studies of COG5- and COG7-deficient mammalian cells. J Biol Chem (2005) 2.53

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51

Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48

A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet (2004) 2.47

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45

Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39

Recapitulation of short RNA-directed translational gene silencing in vitro. Mol Cell (2006) 2.38

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34